Online supplement

Cystic fibrosis registries diagnosis inclusion Criteria

Patients captured on the Canadian Cystic Fibrosis (Registry (CCFR) and the South African CF Registry (SACFR) for the calendar year 2018 were included according to the diagnostic criteria below. For both countries 1) patients consented to have their data collected by the registries and 2) were alive in the year 2018.

Diagnostic Inclusion Criteria:

Canadian Registry:

For a diagnosis of CF, the patient must meet the standard guidelines for having CF (based on clinical symptoms, sweat testing, genotyping; J Pediatr 2008).

SACFR:

Two sweat tests value > 60 mmol/L chloride: CF diagnosis accepted

One sweat test value > 60 mmol/L chloride or sweat conductivity > 90 mmol/L and DNA Analysis/Genotyping – two identified disease-causing CF mutations as reported in CFTR2 database: CF diagnosis accepted; or

Sweat value less than or equal to 60 mmol/L chloride then both these should be fulfilled:

- a. DNA Analysis/Genotyping two identified disease-causing CF mutations; and
- b. Clinical Presentation consistent with typical or atypical CF.

Sweat conductivity without DNA confirmation of two disease causing CFTR mutations as reported in CFTR2 database will be accepted for SA registry only if both following criteria are met:

- a. clinical presentation consistent with typical CF
- b. at least two separate sweat conductivity measurements ≥ 90 mmol/l

Table S1. Explanation of data variables extracted from the Canadian and South African Cystic Fibrosis Registries

Variable	Description		
Demographic Data			
Age	Calculated as age in years from Date Of Birth		
	(DOB) to 31 December 2018. DOB was set to		
	the 15 th of the month in both registries to		
	protect confidentiality.		
Sex	Male or Female		
Ancestry/Ethnicity	South Africa	Canada	
	Caucasian	Caucasian	
	Black African	Black	
	Other: mixed Race,	Other: Asian, South	
	Asian, Indian	Asian,	
	Unknown	First Nations People,	
		Hispanic, two or more	
		races	

	Unknown	
Diagnosis		
Diagnosed by Newborn screening	Yes, No	
	Not available in SA	
Meconium Ileus	Yes, No or Unknown	
Age of Diagnosis	Calculated from DOB to Date of Diagnosis in	
	months.	
Genotype categorised	Categorised as:	
	p.Phe508del homozygous (Yes/No)	
	p.Phe508del heterozygous (Yes/No)	
	Other /Not p.Phe508del Unknown	
CFTR mutation class	Categorised as:	
CFTK IIIutation class	Class I-III (minimal function)	
	Class IV-VI (residual function)	
Mutation Allele Frequency	Frequency of 10 most frequently occurring	
Mutation Ancie Frequency	Allele mutations	
	Includes category for unknown mutation	
Sweat Test	Chloride value in mmol/L	
oweat rest	If two chloride values are recorded the first	
	sweat test value should be calculated for that	
	patient for analysis.	
Sweat Conductivity	Conductivity value in mmol/L	
(SACFR only)	If two conductivity values are recorded the first	
,	value should be calculated for that patient for	
	analysis.	
Lung Function		
FEV ₁ Litres	The best pre-bronchodilator FEV ₁ value (litres)	
	for the 2018 calendar year is selected.	
	Includes children 6 years and older at date of	
	lung function	
	Excludes lung function measurements taken	
	after lung transplant	
	Date of this measurement collected for	
	nutrition and GLI calculations	
FEV ₁ percentage predicted value (%)	Calculated according to Global Lung Index (GLI)	
	using the best pre-bronchodilator FEV ₁ value	
NI. datata	(litres) for the 2018 calendar year.	
Nutrition Pancreatic Status in 2018	Determined by focal electors measurements	
ranciedlic Status III 2018	Determined by fecal elastase measurements and/or prescription of pancreatic enzyme	
	replacement therapy. Pancreatic Sufficient	
	Pancreatic Insufficient	
	Unknown	
Weight (Kg)	Weight at the time of best pre-bronchodilator	
	FEV ₁ value for 2018 is selected.	
	If no FEV ₁ recorded for the year, the last weight	
	measurement of the year is selected.	
	Date of this measurement collected for	

Length/height (cm)	Height at the time of best pre-bronchodilator
	FEV ₁ value for 2018 is selected.
	If no FEV ₁ recorded for the year, the last height
	measurement of the year is selected.
	Date of this measurement collected for
	nutrition calculations.
Nutrition classification	Weight in kg
	Length in cm
	BMI – kg/m2 for patients >18 years
	BMI z-score (BMIz) parameters calculated
	according to World Health Organisation
	references equation children 0-19 years.
Microbiology	
Any Isolates in 2018	Any Pseudomonas isolated in 2018
,	Any MRSA isolated in 2018
	Any NTM isolates in 2018
	Recorded as: Yes, No or Unknown
	*Other infections and chronic infection status
	of specific infections could not be sufficiently
	harmonized between countries to permit
	meaningful comparisons.
Complications	
Cystic Fibrosis Related Diabetes in 2018	Yes, No or Unknown
	Diagnosis of CF related diabetes requiring
	insulin. This includes people who have impaired
	glucose tolerance in Canada but not South
	Africa. If someone has Type 1 diabetes or
	juvenile diabetes, this can be included under
	the category of 'CF-related' diabetes.
Liver cirrhosis/portal hypertension	Yes, No, or Unknown
	Includes clinical (hepatosplenomegaly),
	radiologic (U/S, CT scan that shows enlarged
	spleen or nodular liver), pathologic (liver
	biopsy) evidence of cirrhosis and splenomegaly
	which implies portal hypertension or if there is
	endoscopic evidence of oesophageal or gastric
	varices in the reporting year. If a patient only
	has elevated liver enzyme tests with no
	evidence of cirrhosis or portal hypertension, do
	NOT check this complication.
	In Canada cirrhosis was recorded between
ADDA	2015-2018 ensuring the most recent estimate.
ABPA	Yes, No or Unknown in 2018.
	ABPA by a physician based on clinical judgment
	ABPA by a physician based on clinical judgment,
	biochemistry or other laboratory testing in the
Thoranics	reporting year.
Therapies	
Pulmonary	ly a u i
hypertonic saline	Yes, No or Unknown

	minimum of 3 months of therapy in the	
	reporting year	
rhDNase	Yes, No or Unknown	
	minimum of 3 months of therapy in the	
	reporting year	
macrolides	Yes, No or Unknown	
	minimum of 3 months of therapy in the	
	reporting year	
Inhaled antibiotics	Yes, No or Unknown	
	minimum of 3 months of therapy in the	
	reporting year	
	Yes, includes any inhaled treatment	
	preparation from the SA and Canadian	
	registries including: gentamycin, amikacin,	
	aztreonam, tobramycin, colistin, levofloxacin,	
	vancomycin, or any other inhaled antibiotic	
Number of IVI courses per year	Yes, No or Unknown	
	If Yes – 1/2/3/4/5 or more	
	Canadian Registry: Combining variable for	
	pulmonary admission and Home IV events	
GIT		
Pancreatic Enzyme Replacement Therapy	Yes, No or Unknown	
Transplant in 2018		
Received Liver Transplant in 2018	Yes, No	
Received Liver Transplant prior to 2018	Yes, No	
Received Lung Transplant in 2018	Yes, No	
Received Lung Transplant prior to 2018	Yes, No	
Modulators		
CFTR Modulators (any)	Yes , No	
Deaths		
Number of Deaths in 2018		
Age of death	Calculated in years from DOB to Date of Death	